Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer
about
Prostate cancer stem cells: the role of androgen and estrogen receptorsCellular Plasticity in Prostate Cancer Bone MetastasisRole of periostin and its antagonist PNDA-3 in gastric cancer metastasisEpithelial-mesenchymal transition in prostate cancer: an overview.PHF21B overexpression promotes cancer stem cell-like traits in prostate cancer cells by activating the Wnt/β-catenin signaling pathway.TOP2Ahigh is the phenotype of recurrence and metastasis whereas TOP2Aneg cells represent cancer stem cells in prostate cancer.The androgen receptor plays a suppressive role in epithelial- mesenchymal transition of human prostate cancer stem progenitor cellsContext dependent regulatory patterns of the androgen receptor and androgen receptor target genesBy inhibiting snail signaling and miR-23a-3p, osthole suppresses the EMT-mediated metastatic ability in prostate cancer.Molecular analysis of CD133-positive circulating tumor cells from patients with metastatic castration-resistant prostate cancer.Androgen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition.Modulation of macrophage polarization and lung cancer cell stemness by MUC1 and development of a related small-molecule inhibitor pterostilbeneMiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity.Loss of endothelial cell-specific molecule 1 promotes the tumorigenicity and metastasis of prostate cancer cells through regulation of the TIMP-1/MMP-9 expressionNew advances in genitourinary cancer: evidence gathered in 2014.Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy.DNA methylation variations are required for epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in prostate cancer cells.Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.Long non-coding RNA ATB promotes growth and epithelial-mesenchymal transition and predicts poor prognosis in human prostate carcinoma.PCA3 long noncoding RNA modulates the expression of key cancer-related genes in LNCaP prostate cancer cells.PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.Non-coding RNAs Functioning in Colorectal Cancer Stem Cells.CK2 abrogates the inhibitory effects of PRH/HHEX on prostate cancer cell migration and invasion and acts through PRH to control cell proliferation.Investigational serine/threonine kinase inhibitors against prostate cancer metastases.Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate CancerEcotropic viral integration site 1, a novel oncogene in prostate cancer.Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.miR-129-3p controls centrosome number in metastatic prostate cancer cells by repressing CP110.miR-618 Inhibits Prostate Cancer Migration and Invasion by Targeting FOXP2.Expression of P-EGFR and P-Akt protein in esophageal squamous cell carcinoma and its prognosis.microRNA-802 inhibits epithelial-mesenchymal transition through targeting flotillin-2 in human prostate cancerInhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell propertiesKeratin 13 expression reprograms bone and brain metastases of human prostate cancer cellsEstradiol promotes epithelial-to-mesenchymal transition in human benign prostatic epithelial cells.Upregulation of microRNA-4417 and Its Target Genes Contribute to Nickel Chloride-promoted Lung Epithelial Cell Fibrogenesis and Tumorigenesis.Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.Linking Race, Cancer Outcomes, and Tissue Repair.Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression.Selection-free method reveals phenotypic diversity among prostate cancer circulating tumour cells.Aberrant TGF-β Signaling Drives Castration-Resistant Prostate Cancer in a Male Mouse Model of Prostate Tumorigenesis.
P2860
Q26778415-50836D55-1CFB-47B3-8698-6ECFE854436BQ28085013-6885D1E7-9AD9-43C8-9D5E-B1E30F01646EQ28088349-870C0762-E3FA-4E09-86ED-3400CDABD9E4Q33798864-8C2C7D9A-6E6B-4711-BFCE-11D4C9DF03D2Q33827484-11F98A40-D7CB-4351-8736-EC9D79EC2620Q34619422-E2F8C3E8-B97B-4D81-9F4F-E8F0FDB81553Q35604311-298F592E-D240-47F1-83D9-3A3CD84F6D0BQ36067956-53D4BA6D-1D4D-4CB3-81DC-8C483CDED25DQ36356259-D0874F53-96EE-4264-8C61-530AE5A0DBE5Q36440631-24A044B7-BB8B-48AC-98FE-25801475EEF0Q36707740-66F240E5-27FB-4DFA-8FE2-1B7688982B9DQ37457526-91E9A8AB-98EC-42E2-950A-E507ED8FCD7DQ37565167-07AE7C11-30B3-48C6-8E2B-4F3E6282CA28Q37706719-37D022E3-6EEB-450A-9386-B3A4FABBBB84Q38557894-AE98B48D-AF0A-4F40-B553-498F16E9B322Q38661520-3E8C0EC4-4C1A-4DBC-9EFF-67F88C1AA1FDQ38743845-43C1F633-935B-448C-BD49-B87CE0D9A7DDQ38750022-A58A6A72-4D27-420C-9808-050356191C14Q38771232-3D8E1590-706F-4E3A-BD21-8EBEC7AFB73AQ38787568-D12BAEA0-BBF9-4E3B-881E-89D6CA6FA165Q38825075-A8078FD3-E06C-457B-898D-925AB0A28FBEQ38940597-50937FFC-DD88-4AAA-9118-3A14E300F4C3Q38992187-76918F23-A70C-4032-8455-3CE755D2F20BQ39021945-5FB42C5A-779F-4209-9196-24DBB8E33A95Q39152842-E6DDB7A3-ED66-4926-90B1-02BBD8F96032Q39401617-8B8981CC-1262-429C-840E-A3FA855B55F2Q39867322-8CFC8348-910F-4CBB-9A2F-14AB9BF430DFQ39966525-344719D9-35E9-43D7-8DDD-FC8F8F139D58Q41243073-3C34DE42-7C66-4C75-96D8-64C4C820B589Q41613206-BBA1B72A-906B-43F0-81EC-AD6B4DD8EFEDQ41824632-B1194654-6C9B-4401-BF48-7807D9BB8257Q42078200-7DF615FC-160D-4A05-B528-1B600BB2B8D6Q42315527-89B9C43E-DFC2-4CCC-ABA7-F34395922B61Q42514114-4D667B0A-EB3D-4BF4-B9F3-C7DE0E0185F7Q47108395-7E6FFEF7-F80E-420F-A9F0-3821514BBB51Q47291146-A41EBE53-1077-4F30-92B5-678350D00DDAQ47839645-F0D0F6DA-CA05-4727-9E50-B86030491761Q49483643-1C3547E1-B68F-4874-8424-6EB5D98C8E12Q50142579-8D8DB50F-E90F-4DE3-A9ED-3930B78E2C0EQ51092129-8E273746-677F-4914-9E98-88E5D9CB935B
P2860
Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Contributions of epithelial-me ...... resistance of prostate cancer
@en
Contributions of epithelial-me ...... resistance of prostate cancer.
@nl
type
label
Contributions of epithelial-me ...... resistance of prostate cancer
@en
Contributions of epithelial-me ...... resistance of prostate cancer.
@nl
prefLabel
Contributions of epithelial-me ...... resistance of prostate cancer
@en
Contributions of epithelial-me ...... resistance of prostate cancer.
@nl
P2093
P2860
P356
P1433
P1476
Contributions of epithelial-me ...... resistance of prostate cancer
@en
P2093
P2860
P2888
P356
10.1186/1476-4598-13-55
P5008
P577
2014-03-12T00:00:00Z
P5875
P6179
1018527775